WELCOME BACK TO OUR SHAKE OR IS
EVERYONE
WHICH IN THE SUN AND SCALES
TECHNOLOGIES AND HEALTHCARE
SPACE ANNOUNCED IT HAS RAISED
$100 MILLION FOR ITS
NEW FUND AJAX 3 JOINING US NOW
TO DISCUSS IS DUE CROWLEY WHO
IS THE CEO OF
AJAX SO SUCH A PLEASURE TO HAVE
YOU WITH US TODAY WE'VE GOT TO
START WITH THE OBJECTIVE OF THE
FUND AND THE MISSION OVERALL
FOR AJAX.
>> THANKS FOR HAVING ME SO THE
OBJECTIVE OF THE FUND IS TO
REDEPLOY PEOPLE THAT WORKED WAS
BEING COMPANIES THAT HAVE BEEN
A SUCCESSFUL PREVIOUSLY AND PUT
THEM INTO AREAS WHERE THEY HAVE
REALLY DEEP DOMAIN EXPERTISE
TO SCALE. BOTH FROM A FINANCING
STANDPOINT AND FROM AN
OPERATIONAL STANDPOINT. SO THE
OBJECTIVE IS TO
GROW COMPANIES. WE'RE AGNOSTIC
TO STAGE WE FOCUSED MOSTLY ON
COMPANIES THAT WE THINK CAN
REALIZE VALUE RETURNS IN
48 MONTHS IMPORTANT THAT WE
FOCUS ON COMPANIES THAT WE FEEL
LIKE WE ARE BEST IN THE WORLD
THAT. BASED ON HAVING RUN
COMPANY'S NET IN THOSE SPACES
BEFORE.
>> OK SO WHAT ARE SOME OF THE
MOST PROMISING AN INNOVATION
THAT COULD COME OUT OF THIS
THAT YOU WANT TO WORK ON.
>> OK SO I THINK THERE'S BEEN A
TRANSITION OVER THE LAST 20
YEARS SO 20 YEARS AGO TO
CARDIOLOGY WAS AT THE FOREFRONT
OF INNOVATION AND THEN IT
BECAME PERIPHERAL VASCULAR AND
WE'VE
SEEN TREMENDOUS. INNOVATION IN
ONCOLOGY AND CANCER AND WHAT'S
HAPPENING NOW IS THAT DATA
PROCESSING AND
AI MACHINE LEARNING IS ENABLING
A TRANSITION FROM A COST MODEL
TO A
CARE MODEL AND YOU'RE
SEEING A BURGEONING OF NEW
COMPANIES THAT ARE TAKING
ADVANTAGE OF THAT TRADITIONAL
MEDTECH COMPANIES THAT ARE
TRYING TO FUSE WITH AI MACHINE
LEARNING TO ENABLE. PATIENTS TO
BE
TREATED BETTER TO GET BETTER AT
IT DOES SEEM TO INCREASE SAFETY
AND 2.
PRODUCE LONG-TERM EFFECTS.
I THINK IT WORSE AND ENDING ONE
OF THAT OF THAT OPPORTUNITY AND
YOU'RE GOING TO SEE AN ENORMOUS
AMOUNT OF INVESTMENT AND THAT
OVER THE NEXT 5 TO 7 YEARS AND
AJAX IS A IS FUNDED AND
OPERATED TOO TO CAPITALIZE ON
THAT.
>> WHAT ARE SOME OF THE MOST
PROMISING TECHNOLOGICAL
INNOVATIONS IN MEDTECH RIGHT
NOW AND WHERE YOU PARTICULARLY
THE CA JACK'S GETTING MOST
INVOLVED IS
IT ON THE THE HOSPITAL SIDE OR
THE PRACTITIONER SIDE WAS A
MORE SO
ON THE CUSTOMIZATION FOR THE
END CONSUMER SITE.
>> GREAT POINT A GREAT QUESTION
I THINK SEE THE REAL FOCUS
HAS TO THE ON IMPROVING
DIAGNOSTIC SO THAT YOU
CAN IMPROVE SPECIFIC
SPECIFICITY OF THE DISEASE AND
THEN BEING ABLE TO TAKE THAT
PATIENT THROUGH TO TREATMENT
AND THEN HAVE FOLLOW-UP SO LIKE
I TALKED ABOUT THE BEGINNING
IT'S US CARE MODEL, I THINK
THERE ARE TREMENDOUS
AREAS IN ON I THINK THERE'S
TREMENDOUS AREAS IN CARDIOLOGY
I THINK
THERE THERE'S VERY VERY
SIGNIFICANT OPPORTUNITY TO
DO IT. IN AREAS OF DIAGNOSTICS
LIKE AN ECHO AND IN CTE A
CARDIAC SEE TOO SO I VIEW MY
AREA WHICH IS
PRIMARILY IN MEDICAL DEVICES IS
BEING INFORMED AND EMPOWERED BY
BY AI AND LOOK
AND MACHINE IN THOSE IN THOSE
SPECIFIC CATEGORIES.
>> AND THE FALLOUT OF THERE ARE
KNOWS HOW MUCH.
>> IT'S MORE SCRUTINY. DO YOU
THINK COMPANIES LIKE YOURS
HAVE.
FROM INVESTORS FROM YOU KNOW,
LET'S SAY COMPARED TO BEFORE.
>> YEAH, I
THINK A LOT AND I THINK THE BAR
IS HIGH. I THINK THIS ASSET
CLASS
HAS BEEN HISTORICALLY A REALLY
TOUGH ASSET CLASS TO MAKE MONEY
IN FOR INVESTORS RETURNS ON
AVERAGE HAD TAKEN 8.6 YEARS.
ALL OF THAT NEEDS TO CHANGE AND
I
THINK THAT THERE ARE BUNCH OF
THE STUDENT FESTERS WHO